We attempted to clarify the therapeutic capability of antagonists of the farnesoid X receptor (FXR), a nuclear receptor that regulates lipid and bile acid metabolism. Notably, compound-T1 exhibited beneficial effects on both blood non-HDL-cholesterol and HDL-cholesterol, which are thought to involve enhancement of cholesterol catabolism and apolipoprotein A-I production. These findings aid the understanding of the antidyslipidemic potential of FXR antagonists with a unique lipid and bile acid modulation.
| INTRODUCTION
High blood cholesterol is a risk factor for cardiovascular events.
1,2 3-Hydroxymethyl 3-glutaryl-CoA reductase inhibitors, also known as statins, markedly reduce both blood cholesterol and cardiovascular risk in hyperlipidemia patients. [3] [4] [5] However, for patients who cannot achieve their cholesterol-lowering targets with statins, owing to insufficient efficacy or adverse effects, nonstatin agents are also effective as an alternate or add-on therapy to statins. 6 One such nonstatin agent is cholestyramine, a bile acid sequestrant, which forms a complex with bile acids in the intestine and is then eliminated into feces. Through the augmentation of bile acid synthesis and cholesterol catabolism, cholestyramine demonstrated a significant reduction in blood cholesterol. 7, 8 A recent meta-analysis and large-scale epidemiologic analysis suggested that the cholesterol-lowering effects of bile acid sequestrants, including cholestyramine, may contribute to the prevention of cardiovascular diseases. 9 Another nonstatin medication is the cholesterol absorption inhibitor ezetimibe, which targets intestinal uptake of dietary and biliary cholesterols; good efficacy and tolerability of combination therapy with statin and ezetimibe have been reported. 10 Another approach aimed at the reduction in cardiovascular risk is the increase in blood high-density lipoprotein (HDL)-cholesterol levels 11 by the inhibition of cholesteryl ester-transfer protein (CETP), which mediates transfer of cholesteryl ester from HDLs to atherogenic lipoproteins. Clinical trials involving torcetrapib, the first CETP inhibitor, were terminated early owing to off-target toxicity, 12, 13 and despite remarkable increases in HDL-cholesterol, torcetrapib did not reduce the progression of atherosclerosis. 14, 15 The definitive clinical efficacies of CETP inhibition are under investigation in the ongoing REALIZE study of anacetrapib, a more recent CETP inhibitor. 16 As a possible concept for another novel nonstatin agent, we focused on the inhibition of farnesoid X receptor (FXR), a member of the nuclear receptor superfamily. FXR is expressed at high levels in tissues involved in bile acid metabolism such as the liver, intestine, and kidney. 17, 18 In the liver, FXR indirectly suppressed expression of cholesterol 7a-hydroxylase (CYP7A1), a rate-limiting enzyme in the cholesterol catabolic pathway, 19 and also directly downregulated the expression of apolipoprotein A-I, a major protein constituent of HDL. 20 We therefore hypothesized that repression of FXR would improve dyslipidemia via both non-HDL-cholesterol reduction and HDL-cholesterol elevation, and we successfully confirmed that a synthesized FXR antagonist, compound-T3, displayed these blood changes in cynomolgus monkeys. 21, 22 In this study, to clarify the 
| MATERIALS AND METHODS

| Drugs
Compound-T1 was synthesized at Takeda Pharmaceutical Co., Ltd (Osaka, Japan). Ezetimibe was purified from commercially available tablets at Takeda Pharmaceutical Co., Ltd. Torcetrapib was synthesized at KNC Laboratories Co., Ltd (Hyogo, Japan). Cholestyramine, chenodeoxycholic acid (CDCA), and 7a-hydroxy-4-cholesten-3-one (C4) were purchased from Sigma-Aldrich Japan (Tokyo, Japan).
| Nuclear receptor panel assays
The agonistic and antagonistic activities of human nuclear receptors, FXR and PPARs PPARa, PPARd, and PPARc were measured as previously described. 23, 24 The agonistic and antagonistic activities for the human retinoid X receptor-a (RXRa) and the human liver X receptors (LXRs) LXRa and LXRb were also measured. Briefly, the reporter construct for the RXRa reporter gene assay, pGL3-DR1 9 4-tk-luc, was created by the insertion of four copies of direct repeat 1 element (AGGTCA-N-AGGTCA) upstream of the herpes virus thymidine kinase promoter and the luciferase reporter gene. To construct the LXRa and LXRb reporter gene assays, pGL3-DR4 9 4-tk-luc was generated by the insertion of four copies of direct repeat 4
(AGGTCA-NNNN-AGGTCA) at the same position as pGL3-DR1 9 4-tk-luc.
COS-1 cells were maintained in DMEM supplemented with 10%
fetal bovine serum at 37°C under 5% CO 2 . Cells were transfected in F150 flasks (Corning, NY, USA) with pMCMVneo-hRXRa and pGL3-DR1 9 4-tk-luc for RXRa assays, pMCMVneo-hRXRa, pMCMVneo-
hLXRa, and pGL3-DR4 9 4-tk-luc for LXRa assays, and pMCMVneo-hRXRa, pMCMVneo-hLXRb, and pGL3-DR4 9 4-tk-luc 
| Animals
All animal experiments were performed in accordance with the guidelines of the Takeda experimental animal care and use committee. Five-week-old male Golden Syrian hamsters were purchased from Japan SLC, Inc. (Shizuoka, Japan), and maintained in a room with controlled temperature and humidity conditions of 20-26°C and 40%-80%, respectively, under a 12-hour light/dark cycle. The hamsters were allowed free to access to water and received a commercial standard chow diet (CE-2; CLEA Japan Inc., Tokyo, Japan).
| Single-dose study
Hamsters were fed with a Western-type diet (a chow diet containing 0.15% cholesterol and 15% nonsalt butter, Oriental Yeast Co., Ltd, Tokyo, Japan) and housed individually in cages after the age of 7 weeks. Eight-week-old hamsters fed with a Western-type diet for 1 week were orally administered compound-T1 (0.3, 1, and 3 mgÁkg À1 in a 0.5% methylcellulose solution). Hamsters in the control group were treated with 0.5% methylcellulose vehicle solution only. The measurements of plasma C4 levels were conducted on blood samples collected from the orbital vein under nonfasting conditions at 4, 8, and 24 hour after administration (n = 6).
| Multiple-dose study
Hamsters were fed with a high-fat diet (a chow diet containing 10.3% nonsalt butter, Oriental Yeast Co., Ltd) and housed individually in cages after the age of 6 weeks. After high-fat diet feeding for 1 week, drug treatments were commenced at the age of 7 weeks.
Specifically, hamsters were divided into six groups for experiment 1 ), n = 6); all groups were matched for body weight and plasma lipid levels.
Food consumption was determined for each animal every day. Compound-T1, ezetimibe, and torcetrapib were suspended in 0.5% methylcellulose solution and administered by gavage once per day for 9 days. Cholestyramine was mixed in the 10.3% butter-containing powder diet such that the final diet contained 1% cholestyramine. Dosage was calculated from the cholestyramine content of the feed and the average food consumption during the first 7 days of drug administration. The control group was administered with a vehicle solution of 0.5% methylcellulose.
Blood samples were collected from the orbital vein using heparin as an anticoagulant on the mornings of days 1 and 8 under nonfasting conditions, which were regarded as pre-and post-treatment samples, respectively, and used for measurements of the plasma lipid levels. Feces were collected from each hamster over a 48 hour period on days 6-8 of drug administration. The hamsters were sacrificed under anesthesia 4 hour after the final drug treatment on day 9 as described above; pieces of the livers were collected and transferred immediately into storage at À30°C for lipid level measurements and at À80°C for gene expression measurements.
| Measurement of plasma C4 levels
Plasma C4 levels were measured following the method described in our previous report. 23 Briefly, 25 lL plasma was mixed vigorously with 10 lL of 7b-hydroxy-4-cholesten-3-one (50 lgÁmL À1 in dimethylsulfoxide; Calbiochem, USA), as an internal standard, and 500 lL acetonitrile, and then the mixture was sonicated for 5 minutes. After centrifugation, 100 lL supernatant was processed using a HPLC system (ClassVP; Shimadzu, Japan) fitted with a Nova-Pak C18 steel column (Waters Corporation, USA), and analyzed with 95% acetonitrile (flow rate: 1 mLÁmin
À1
) as the mobile phase. The absorbance of C4 was detected at 241 nm; absorbance areas of C4 and the internal standard were calculated, and the concentrations of C4 were quantified against an internal standard. profiles, hamsters were sacrificed under anesthesia 4 hour after the final drug administration on day 9, and blood samples were collected from the abdominal aorta. After centrifugation, the obtained plasma samples were analyzed using LipoSEARCH technology (Skylight Biotech, Akita, Japan), in which plasma lipoproteins were fractionated by HPLC into 20 subfractions according to particle size.
| Blood biochemistry
| Measurement of fecal total bile acid and lipid levels
Feces were dried for 6 hour at 90°C. For fecal total bile acid measurement, dried feces (approximately 0.2 g) were homogenized in distilled water (2 mL) and then shaken at 37°C for 15 minutes after the addition of t-butanol (2 mL). After centrifugation twice, the 
| Measurement of hepatic lipid levels
The frozen liver samples (approximately 1.0 g) were homogenized by the addition of 3.35% sodium sulfate solution (9 mL) and shaken for 10 minutes after the addition of a 3:2 solution of hexane-isopropanol (3:2) solution. Subsequently, 100 lL of the solution was evaporated to dryness and solidified at 50°C in a nitrogen atmosphere to form a dried residue. The residue was dissolved in a 100 lL of diox- 
| Quantitative real-time polymerase chain reaction (PCR)
The frozen liver samples (approximately 100 mg) were homogenized in ISOGEN solution (Nippon Gene Co., Ltd, Tokyo, Japan) and total RNA was extracted and purified using the RNeasy Mini Kit (QIAGEN K.K., Tokyo, Japan). mRNA expression levels were measured using a Table S1 ). Expectedly, these three agents The next study compared compound-T1 and torcetrapib in the hamster model. Compound-T1 was dosed at slightly higher levels and was expected to cause HDL-cholesterol elevation equivalent to torcetrapib. The changes in plasma parameters are summarized in Figure 4 (see also Table S2 ). Torcetrapib significantly elevated HDLcholesterol level but did not lower non-HDL-cholesterol and TG levels, which was in contrast to compound-T1. Although no changes in body weight were observed in all groups, a significant reduction in food intake was observed in the 10 mgÁkg À1 Áday À1 of compound-T1-treated group (À22.5%, data not shown).
| Statistical analysis
To perform a detailed comparison between the HDL-cholesterolelevating effects of compound-T1 and torcetrapib, we conducted lipoprotein profiling by HPLC gel filtration system ( Figure 5 ). Compound-T1 dose-dependently reduced the levels of both very lowdensity lipoprotein (VLDL) and low-density lipoprotein (LDL) with no The selectivity of compound-T1 for human nuclear receptors was measured as described in the Methods section.
F I G U R E 2
Effects of compound-T1 on plasma C4 levels. Timedependent changes in hepatic gene expression of plasma C4 were measured in samples collected after a single administration of compound-T1 to high-fat diet-fed hamsters. Each value represents the mean AE SEM (n = 6). The measurement procedures are described in the Methods section. Statistical analysis was carried out using one-tailed Williams' test ( † P ≤ .025 vs control) SHINOZAWA ET AL. , compound-T1 also increased HDL levels with no change in the peak value of particle size, but an increase larger HDL particles (fraction number 16) was observed, especially at the higher treatment concentration. In contrast, torcetrapib produced a more marked increase in HDLs with a larger particle diameter; in particular, a dose of 100 mgÁkg 
| Comparative studies on fecal and hepatic lipid profiles in a dyslipidemic hamster model
The changes in fecal lipid content after treatment with compound-T1, ezetimibe, and cholestyramine are summarized in Figure 6A .
Both compound-T1 and cholestyramine significantly increased fecal total bile acid content, while ezetimibe increased both fecal total cholesterol and TG content. No other significant changes were observed in all groups.
Next, the changes in fecal lipid content were compared between compound-T1 and torcetrapib, and are summarized in Figure 6B .
Compound-T1 dose-dependently increased fecal total bile acid content, while torcetrapib resulted in a significant decrease. A significant reduction in fecal total cholesterol was observed in both groups receiving the highest dosage of compound-T1 (10 mgÁkg To confirm the FXR antagonistic activities of compound-T1 after multiple doses, we measured the hepatic expression levels of CYP7A1. Hepatic CYP7A1 mRNA levels were dose-dependently increased in the compound-T1-treated groups and in the cholestyramine-treated group. There were no significant changes in the ezetimibe-treated groups (Figure 8 ).
| Effects of compound-T1 on apolipoprotein A-I production in Huh-7 cells
To elucidate the mechanism of the HDL-cholesterol-elevating effects of compound-T1, we investigated its effect on apolipoprotein A-I production using the human hepatoma Huh-7 cell line under physiological CDCA conditions. Apolipoprotein A-I secretion was significantly reduced by the addition of 30 lmolÁL À1 CDCA, and this reduction was dose-dependently rescued by compound-T1 with an ED 50 value of 1.8 nmolÁL À1 (Figure 9 ).
| DISCUSSION
We have previously confirmed that a synthesized FXR antagonist, compound-T3, reduced plasma non-HDL-cholesterol levels and also elevated HDL-cholesterol levels in a primate model. 21, 22 However, the development of a rodent model with similar disease conditions to human hyperlipidemia would be still useful for the further comprehension of this new type of agent. However, the rodent animals such as mice, rats, and guinea pigs have different plasma lipid and lipoprotein profiles from humans. 23, 25 Actually, we found that another FXR antagonist, compound-T0, exacerbated dyslipidemia in mice due to enhancement of intestinal lipid absorption via acceleration of bile acid excretion. 26 We think that the difference of the effects of FXR antagonist between primate and mouse models would be due to the difference in regulation of key players relating to lipid and bile acids metabolisms, in particular, the hepatic LDL receptor. 27 In addition, CETP is also a key protein involved in plasma cholesterol transport that transfers cholesteryl ester from HDL to LDL and VLDL. 28 Golden Syrian hamsters are known to develop human-like hyperlipidemia following the feeding of a high-fat diet, [29] [30] [31] and also show both plasma CETP activity 28 and regulation of hepatic LDL receptor. 32 Therefore, we considered that a hyperlipidemic hamster model would be suitable for the purpose described above. To determine the appropriate diet for hamsters, we referenced diet information in nonclinical and clinical studies of orlistat, an antiobesity drug. 33, 34 After the hamsters were fed this butter-rich diet for a week, both plasma levels of cholesterol and triglyceride increased to approximately two and three times the normal level respectively F I G U R E 5 Effects of compound-T1 and torcetrapib on plasma lipoprotein distribution in high-fat diet-fed hamsters. Pooled plasma (n = 6 per group) was collected after repeated drug administrations and then was fractionated by gel filtration HPLC. The measurement procedures are described in the Methods section SHINOZAWA ET AL.
| 7 of 11 (Table S3) . Using this hamster model, herein, we sought to clarify the favorable pharmacological profile of a novel FXR antagonist compound-T1, a potential antidyslipidemic agent, through comparative studies with other nonstatin agents ezetimibe, cholestyramine, and torcetrapib.
The first question in our study was to determine whether the clinical results of other nonstatin agents were consistent in our hamster model. Firstly, ezetimibe, a cholesterol absorption inhibitor, exhibited clinically relevant changes with regard to the plasma non-HDL-cholesterol reduction and fecal cholesterol excretion. 35, 36 Although a significant increase in fecal TG was also found in ezetimibe-treated hamsters, as reported in a previous study using an obese rodent model, 37 the dramatic effect of ezetimibe on TG excretion has not been reported in a clinical setting. However, an inhibitory effect on the intestinal production of chylomicrons, which consist largely of TG, was reported in patients with hyperlipidemia. 38 Therefore, we assumed that the increased fecal TG in ezetimibe-treated hamsters might result from its intervention in chylomicron TG Cholestyramine also elevated hepatic CYP7A1 expression and fecal total bile acid content, which suggested the mechanism of action occurred through the activation of the cholesterol catabolism pathway. In addition, the CETP inhibitor torcetrapib resulted in a remarkable increase in HDL-cholesterol, similar to those observed in clinical trials. In the present study, torcetrapib did not induce changes in either of fecal cholesterol and bile acid contents, which suggested that torcetrapib did not increase the overall amount of lipid excreted out of the body. The analysis of plasma lipoprotein subclass revealed that torcetrapib increased the fraction of HDL with a larger particle diameter. Although these findings were consistent with clinical observations, 41, 42 the significance of large HDL particles has not been determined. However, it was reported that subjects with a genetic CETP deficiency, who are expected to have high levels of larger HDLs, 43 had an increase in coronary heart disease in some analysis. 44, 45 The large HDL particles warrant further investigation both subfractionally and functionally.
As discussed above, our hamster model reflected the most of clinical responses of nonstatin agents; therefore, the next question was to determine how the FXR antagonist exhibited its antidyslipidemic effects. In this model, compound-T1 significantly lowered plasma non-HDL-cholesterol and elevated plasma HDL-cholesterol.
FXR is reported to regulate the expression genes involved in SHP-1
and apolipoprotein A-I in the liver; in particular, the upregulation of SHP-1 by FXR decreases the expression of CYP7A1. 19, 20 This was consistent with the compound-T1-induced changes observed in this study: elevated hepatic expression of CYP7A1 decreased hepatic cholesterol and increased fecal bile acids. It was suggested that compound-T1 accelerated both the catabolism of cholesterol to bile acids and their excretion into feces. Plasma TG levels were significantly decreased in hamsters that received 6 mgÁkg À1 Áday À1 compound-T1 or greater, but it was assumed that the higher doses constitute an excessive dose, because a reduction in food intake (- . In addition, in human hepatoma Huh-7 cells, compound-T1 concentration-dependently rescued the CDCAinduced reduction in apolipoprotein A-I production, and the ED 50 value was 1.8 nmolÁL
À1
, which was a similar concentration to the IC 50 value in the human FXR antagonism reporter gene assay (Table 1) . Additionally, when an oral dose of 1.0 mgÁkg À1 compound-T1 was administered to hamsters fed a standard diet, the maximum plasma concentration was 12.4 nmolÁL À1 and the AUC 0-24 h liver:-plasma ratio was approximately 400:1 (data not shown). Despite the consideration of interspecies differences, it was expected that the required amount of compound-T1 to enhance apolipoprotein A-I production would be available in the livers of the compound-T1-treated hamsters in the present study. To the best of our knowledge, this is the first pharmacological evaluation of an FXR antagonist in a dyslipidemic hamster model.
The final question addressed in this study was whether the FXR antagonist possessed advantages over other nonstatin agents. Based on our findings described above, it has been suggested that the FXR antagonist could uniquely modulate both non-HDL-cholesterol and HDL-cholesterol metabolism. Specifically, ezetimibe exhibited a large reduction in plasma non-HDL-cholesterol, but as discussed above, its mechanism was unrelated to the one of compount-T1. In contrast, cholestyramine and compound-T1 acted through similar mechanisms; both agents activated the cholesterol catabolism pathway. However, cholestyramine required a relatively high dose to confer a sufficient cholesterol-lowering effect; this was also consistent with clinical F I G U R E 8 Effects of compound-T1, ezetimibe, and cholestyramine on hepatic CYP7A1 expression in high-fat diet-fed hamsters. Hepatic CYP7A1 expression levels were measured in livers collected after repeated administration of compound-T1, ezetimibe, and cholestyramine. Each value represents the mean AE SEM (n = 6). The measurement procedures are described in the Methods section. Statistical analysis vs the control was carried out using Student's ttest (**P ≤ .01 vs control) or one-tailed Shirley-Williams test ( † P ≤ .025 vs control) F I G U R E 9 Effect of compound-T1 on apolipoprotein A-I secretion in CDCA-treated Huh-7 cells. Apolipoprotein A-I concentration in cell supernatant was measured with a sandwich ELISA method, as described in the Methods section. Each value represents the mean AE SEM (n = 3). Statistical analysis was carried out using Student's t-test (**P ≤ .01 vs control) or one-tailed Williams' test ( † P ≤ .025 vs CDCA(+)) observations as described above. A high dosage requirement can sometimes affect patient drug compliance. 46 In this respect, compound-T1 would be therefore superior to cholestyramine. Additionally, in the present study, compound-T1 did not result in a large change in HDL particle size, but torcetrapib did. Future studies are needed to clarify this, but it would be important to investigate whether increased HDL particles can promote the reverse cholesterol transport system to cause cholesterol efflux from atherosclerotic lesions to the liver and feces; in particular, we recommend a focus on apolipoprotein A-I, which has been reported to be a key factor in the effective promotion of beneficial HDL metabolism. 47 Indeed, intravenous infusion of a variant of apolipoprotein A-I-phospholipid complexes resulted in the regression of atherosclerosis in patients with acute coronary syndromes. 48 In this regard, increased antiatherosclerotic effects may be expected from compound-T1, 
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